Thursday, 20th March 37th TROG Cancer Research Annual Scientific Meeting 2025

Presenter:

Dr. Anthony Wilkinson
Senior Director of Medical Affairs
Varian USA

Bio:

Dr Anthony Wilkinson (BPharm, MBBS, LLB, PhD) is a registered medical practitioner and pharmacist in Australia and a lawyer admitted to the Supreme Court of Queensland (Australia) and Oregon State Bar (USA). He has over 20 years’ experience in the medical field working initially as a community and hospital pharmacist and then as a hospital based medical practitioner. He left hospital medicine to work as a drug regulator (with the Australian Therapeutic Goods Administration - TGA) and then joined the medical device industry, working as a Medical Director with specific interests in clinical trials, regulation, medical affairs, compliance and health economics. Dr Wilkinson has also worked as a life science IP and regulatory lawyer with an international law firm in Hong Kong. He is currently the Director of Global Field Medical for Varian.

• Breast Working Party Update, Open Trials and Opportunities - Steven David
• MRC/BIG 2-04 | TROG 11.01 SUPREMO: A phase III randomised trial to assess the role of adjuvant chest wall irradiation in 'intermediate risk' operable breast cancer following mastectomy. SUPREMO (Selective Use of Postoperative Radiotherapy after MastectOmy) BIG 2-04 - The 10-year results (Cat B, Closed) - Boon Chua
• ICR-CTSU/2024/10088 | TD 24.08 FAST Forward Boost: A UK-wide inclusive and pragmatic randomised phase 3 trial testing the safety and effectiveness of delivering simultaneous integrated boost radiotherapy (RT) in 1-week compared with the standard 3-week RT schedule in people with early breast cancer (Cat B, In development) - Michael Jones
• PMC 17/013| TROG 17.05 AZTEC: A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple-Negative Breast Cancer - Results (Cat C, Closed) - Steven David
• The role of the RT Advanced Practitioner in breast radiation oncology - Anelyn Chui
• Importance of pathology in clinical trials: design & execution to translational research - Sunil Lakhani

• Innovative Trial Design - Andrew Martin
• Teletrial model for fostering primary and satellite site partnerships - Sabe Sabesan
• Designing High-Impact, Cost-Effective Radiation Oncology Trials in 2025 - Steven David
• TROG’s data assets are precious and available for improving research translation - Martin Ebert
• Using Patient-Reported Outcome Measures in Cancer Clinical Trials: Perspectives For and Against a ‘Modular Approach’ - Carrie-Anne Ng

12:45 - Opening and Welcome

12:50 - Case Study 1: Limited Stage Small Cell Lung Cancer

Discussion questions

1. What is the optimal thoracic dose-fractionation schedule
2. What is the optimal treatment sequence between thoracic radiotherapy and emerging novel systemic therapies
3. Is there a role for PCI
4. Assuming there may still be a role for PCI in selected individuals, is the hippocampal-sparing approach the preferred technique
5. What are the next questions that we need to address (medical oncology and radiation oncology)

13:15 - Case Study 2: Extensive Stage Small Cell Lung Cancer

Discussion questions

1. Is there a role for consolidation thoracic radiotherapy
2. If there is still a role for consolidation thoracic radiation therapy in selected individuals, what is the optimal dose-fractionation schedule
3. Is there a role for PCI
4. Is there a role for SRS in brain metastases
5. What are the next questions that we need to address after (medical oncology and radiation oncology)

13:40 - Closing remarks and next steps

Facilitator: Sandra Turner 

Panel Members:

• Murray McLachlan
• Lee Hunt
• Robyn Leonard
• Laird Cameron
• Sabe Sabesan
• Paul Keall
• Jane Ludbrook

• Introduction and update on the TROG Head and Neck portfolio   - Charles Lin
• NRG Head & Neck Cancer Portfolio – Opportunities for TROG-NRG Collaboration - Quynh-Thu Le
• Tumor volume and intensified treatment for head and neck cancer - an invitation from ARTSCAN to TROG  - Gabriel Adrian
• TD 24.02 RATIONAL: Assessing the clinical utility of HPV ctDNA kinetics as a marker of radiologically undetectable residual disease in human papillomavirus-associated oropharyngeal cancer treated with definitive chemoradiotherapy (Cat A, In development) - Lachlan McDowell
• NRG-HN014 | TD 24.02: Randomized Phase III Trial of Peri-operative Immunotherapy with Response-adjusted Surgery versus Standard-of-Care (SOC) Surgery for Resectable Stage III/IV Cutaneous Squamous Cell - Danny Rischin
• R2810-ONC-1788 |TROG 17.11 cPOST: A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous - Danny Rischin
• TD 24.06 RATOC: Rationalisation of adjuvant radiation therapy in good prognosis Human Papillomavirus associated Oropharyngeal Cancer (HPV OPC) treated with trans-oral surgery (TOS). (Cat C, In development) - June Corry

5:10PM - Panel discussion: De-intensification of follow up for treated P16+ OPSCC

Panelists:

• Dr Lachlan MacDowell
• A/Prof Daniel Xing
• Dr Quynh-Thu Le
• Dr Ryan Sommerville
• Prof Chamindie Punyadeera

VENUE: Mercure Brisbane King George Square
DRESS CODE: 80’s Neon

Get ready for a night to remember at the TROG 2025 Gala Dinner— 80’S NEON EDITION! 
Join us for an electrifying evening packed with a dazzling three-course dinner, dance floor vibes, and non-stop entertainment!